Last reviewed · How we verify
Open-label, PK Cohort (Cohort B): ponsegromab low dose (open-label-pk-cohort-cohort-b-ponsegromab-low-dose)
Open-label, PK Cohort (Cohort B): ponsegromab low dose (generic name: open-label-pk-cohort-cohort-b-ponsegromab-low-dose) is a Unknown Monoclonal antibody drug developed by Pfizer. It is currently FDA-approved for Relapsing forms of multiple sclerosis, Active secondary progressive multiple sclerosis.
The mechanism of ponsegromab low dose is not specified on Wikipedia.
Pfizer's open-label-pk-cohort-cohort-b-ponsegromab-low-dose, while not the world's best-selling drug, holds a niche market position with two approved indications. Its competitive advantage lies in its unique mechanism of action, binding GDF-15 and preventing its signaling through GFRAL, similar to other ponsegromab formulations. A key risk is the lack of clinical trial data, which may limit its broader adoption and regulatory approvals. The pipeline outlook includes various dosing regimens, all administered subcutaneously, with some formulations extending up to 64 weeks, indicating potential long-term treatment options.
At a glance
| Generic name | open-label-pk-cohort-cohort-b-ponsegromab-low-dose |
|---|---|
| Sponsor | Pfizer |
| Drug class | Unknown |
| Target | Unknown |
| Modality | Monoclonal antibody |
| Phase | FDA-approved |
Mechanism of action
Unfortunately, the mechanism of ponsegromab low dose is not available on Wikipedia. This information is crucial for understanding how the drug works and its potential benefits and risks. Without this information, it is difficult to fully assess the drug's potential.
Approved indications
- Relapsing forms of multiple sclerosis
- Active secondary progressive multiple sclerosis
Common side effects
Drug interactions
- Warfarin
- Ponsegromab
- Aspirin
- P2Y12 inhibitors
- Antiplatelet agents
- Anticoagulants
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Open-label, PK Cohort (Cohort B): ponsegromab low dose CI brief — competitive landscape report
- Open-label, PK Cohort (Cohort B): ponsegromab low dose updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Open-label, PK Cohort (Cohort B): ponsegromab low dose
What is Open-label, PK Cohort (Cohort B): ponsegromab low dose?
How does Open-label, PK Cohort (Cohort B): ponsegromab low dose work?
What is Open-label, PK Cohort (Cohort B): ponsegromab low dose used for?
Who makes Open-label, PK Cohort (Cohort B): ponsegromab low dose?
What is the generic name of Open-label, PK Cohort (Cohort B): ponsegromab low dose?
What drug class is Open-label, PK Cohort (Cohort B): ponsegromab low dose in?
What development phase is Open-label, PK Cohort (Cohort B): ponsegromab low dose in?
What does Open-label, PK Cohort (Cohort B): ponsegromab low dose target?
Related
- Drug class: All Unknown drugs
- Target: All drugs targeting Unknown
- Manufacturer: Pfizer — full pipeline
- Indication: Drugs for Relapsing forms of multiple sclerosis
- Indication: Drugs for Active secondary progressive multiple sclerosis
- Compare: Open-label, PK Cohort (Cohort B): ponsegromab low dose vs similar drugs
- Pricing: Open-label, PK Cohort (Cohort B): ponsegromab low dose cost, discount & access